OPERATING_VBG ENVIRONMENT_NN REGULATION_NN The_DT international_JJ medical_JJ device_NN industry_NN is_VBZ highly_RB regulated_VBN ._.
Regulatory_NNP requirements_NNS are_VBP a_DT major_JJ factor_NN in_IN determining_VBG whether_IN substances_NNS and_CC materials_NNS can_MD be_VB developed_VBN into_IN marketable_JJ products_NNS and_CC the_DT amount_NN of_IN time_NN and_CC expense_NN that_WDT shouldbe_VBP allotted_VBN to_TO suchdevelopment_NN ._.
National_NNP regulatory_JJ authorities_NNS administer_VBP and_CC enforce_VBP a_DT complex_JJ series_NN of_IN laws_NNS and_CC regulations_NNS that_WDT govern_VBP the_DT testing_NN ,_, approval_NN ,_, manufacturing_NN ,_, labeling_VBG ,_, marketing_NN and_CC sale_NN of_IN healthcare_NN and_CC pharmaceutical_JJ products_NNS ._.
They_PRP also_RB review_VBP data_NNS supporting_VBG the_DT safety_NN and_CC efficacy_NN of_IN such_JJ products_NNS ._.
Of_IN particular_JJ importance_NN is_VBZ the_DT requirement_NN in_IN many_JJ countries_NNS that_WDT products_NNS be_VB authorised_VBN or_CC registered_VBN prior_RB to_TO manufacture_VB ,_, marketing_NN or_CC sale_NN and_CC that_IN such_JJ authorisation_NN or_CC registration_NN be_VB subsequently_RB maintained_VBN ._.
The_DT major_JJ regulatory_JJ agencies_NNS for_IN Smith_NNP &_CC Nephews_NNP products_NNS are_VBP the_DT FDA_NNP in_IN the_DT US_NNP ,_, the_DT Medicines_NNP and_CC Healthcare_NNP products_NNS Regulatory_NNP Agency_NNP in_IN the_DT UK_NNP and_CC the_DT Ministry_NNP for_IN Health_NNP Labor_NNP and_CC Welfare_NNP in_IN Japan_NNP ._.
Payment_NN for_IN many_JJ medical_JJ device_NN products_NNS is_VBZ governed_VBN by_IN reimbursement_NN tariff_NN agencies_NNS ineach_VBP individualcountry_NN ._.
The_DT trend_NN in_IN recent_JJ years_NNS has_VBZ been_VBN towards_IN greater_JJR regulation_NN and_CC higher_JJR standards_NNS of_IN technical_JJ appraisal_NN ,_, which_WDT generally_RB entail_VBP lengthy_JJ inspections_NNS for_IN compliance_NN with_IN appropriate_JJ standards_NNS ,_, including_VBG regulations_NNS such_JJ as_IN good_JJ manufacturing_NN practices_NNS ._.
Smith_NNP &_CC Nephew_NNP believes_VBZ that_IN these_DT recent_JJ changes_NNS will_MD not_RB have_VB a_DT material_NN adverse_JJ effect_NN on_IN the_DT Groups_NNS financial_JJ condition_NN and_CC the_DT results_NNS of_IN operations_NNS ._.
All_DT significant_JJ facilities_NNS within_IN the_DT Group_NNP are_VBP subject_JJ to_TO regular_JJ internal_JJ audit_NN for_IN medical_JJ device_NN regulatory_JJ compliance_NN with_IN national_JJ and_CC Group_NNP standards_NNS and_CC policies_NNS ._.
Smith_NNP &_CC Nephew_NNP believes_VBZ that_IN the_DT Groups_NNS operations_NNS currently_RB comply_VBP in_IN all_DT material_NN respects_VBZ with_IN applicable_JJ environmental_JJ laws_NNS and_CC regulations_NNS ._.
Although_IN the_DT Group_NNP continues_VBZ to_TO make_VB capital_NN expenditure_NN for_IN environmental_JJ compliance_NN ,_, it_PRP is_VBZ not_RB currently_RB aware_JJ of_IN any_DT significant_JJ expenditure_NN that_WDT would_MD be_VB required_VBN as_IN a_DT result_NN of_IN suchlaws_NNS and_CC regulationsthat_NN wouldhave_VBP a_DT material_NN adverse_JJ impact_NN uponthe_NN Groups_NNS financialcondition_NN ._.
PRODUCT_NN LIABILITY_NN The_DT Group_NNP monitors_VBZ the_DT safety_NN of_IN its_PRP$ products_NNS from_IN initial_JJ product_NN development_NN through_IN to_TO product_NN use_NN or_CC application_NN ._.
In_IN addition_NN ,_, the_DT businesses_NNS of_IN the_DT Group_NNP analyze_VB on_IN a_DT worldwide_JJ basis_NN reports_NNS of_IN adverse_JJ reactions_NNS and_CC complaints_NNS relating_VBG to_TO its_PRP$ products_NNS ._.
Each_DT business_NN reviews_VBZ these_DT adverse_JJ reactions_NNS and_CC complaints_NNS and_CC any_DT safety_NN matters_VBZ arising_VBG with_IN independent_JJ medical_JJ advisors_NNS ._.
These_DT conclusions_NNS are_VBP subsequently_RB reviewed_VBN by_IN the_DT Groups_NNS independent_JJ medical_JJ advisor_NN ._.
Product_NN liability_NN is_VBZ a_DT commercial_JJ risk_NN for_IN the_DT industry_NN of_IN which_WDT the_DT Group_NNP is_VBZ a_DT part_NN ,_, particularly_RB in_IN the_DT US_NNP ._.
Smith_NNP &_CC Nephew_NNP has_VBZ implemented_VBN systems_NNS it_PRP believes_VBZ are_VBP appropriate_JJ in_IN respect_NN of_IN loss_NN control_NN techniques_NNS ._.
These_DT include_VBP reporting_VBG mechanisms_NNS to_TO ensure_VB early_JJ notification_NN of_IN complaints_NNS and_CC a_DT legal_JJ department_NN which_WDT manages_VBZ and_CC lawsuits_NNS ._.
The_DT Group_NNP carries_VBZ product_NN liability_NN insurance_NN to_TO cover_VB exposure_NN as_IN far_RB as_IN practicable_JJ ._.
With_IN the_DT exception_NN of_IN the_DT macrotextured_JJ product_NN liability_NN claim_NN ,_, discussed_VBN under_IN Legal_NNP Proceedings_NNP ,_, and_CC Risk_NNP Factors_NNP instances_NNS of_IN loss_NN to_TO the_DT Group_NNP arising_VBG from_IN product_NN liability_NN claims_NNS have_VBP been_VBN covered_VBN either_CC directly_RB by_IN the_DT Group_NNP or_CC by_IN insurance_NN ._.
Apart_RB from_IN the_DT macrotextured_JJ claims_NNS ,_, there_EX are_VBP no_DT individual_JJ product_NN liability_NN claims_NNS ,_, and_CC no_DT group_NN of_IN similar_JJ claims_NNS ,_, that_WDT are_VBP expected_VBN to_TO have_VB a_DT material_NN adverse_JJ effect_NN onthe_NN Groups_NNS financialposition_NN ._.
There_EX can_MD be_VB no_DT assurance_NN that_IN consumers_NNS ,_, particularly_RB in_IN the_DT US_NNP ,_, will_MD not_RB bring_VB product_NN liability_NN or_CC related_VBN claims_NNS that_WDT would_MD have_VB a_DT material_NN adverse_JJ effect_NN on_IN the_DT Groups_NNS financial_JJ position_NN or_CC results_NNS of_IN operations_NNS in_IN the_DT future_NN or_CC that_IN the_DT Group_NNP will_MD continue_VB to_TO resolve_VB such_JJ claims_NNS within_IN insurance_NN limits_NNS in_IN view_NN of_IN changing_VBG legal_JJ doctrines_NNS and_CC attitudes_NNS regardingsuchmatters_NNS ._.
See_VB Risk_NNP Factors_NNP and_CC Loss_NN of_IN Reputation_NN ._.
11_CD RISK_NN MANAGEMENT_NN Smith_NNP &_CC Nephews_NNP products_NNS include_VBP implantable_JJ devices_NNS but_CC are_VBP not_RB life_NN support_NN medical_JJ devices_NNS ._.
If_IN these_DT devices_NNS malfunction_NN ,_, they_PRP could_MD damage_VB or_CC impair_VB the_DT repair_NN of_IN body_NN functions_NNS ._.
Management_NNP believes_VBZ that_IN the_DT Groups_NNS quality_NN ,_, regulatory_JJ and_CC medical_JJ controls_NNS and_CC insurance_NN cover_NN is_VBZ adequate_JJ and_CC appropriate_JJ for_IN this_DT class_NN of_IN products_NNS ._.
The_DT Groups_NNS reputation_NN is_VBZ crucially_RB dependent_JJ on_IN strong_JJ performance_NN in_IN this_DT area_NN and_CC on_IN appropriate_JJ crisismanagement_NN if_IN a_DT serious_JJ medical_JJ shouldoccur_NN ._.
The_DT Board_NNP is_VBZ responsible_JJ for_IN the_DT maintenance_NN of_IN the_DT Groups_NNS systems_NNS of_IN risk_NN management_NN and_CC internal_JJ control_NN and_CC for_IN reviewing_VBG their_PRP$ effectiveness_NN ._.
These_DT systems_NNS ,_, which_WDT accord_NN with_IN the_DT Turnbull_NNP Guidance_NNP and_CC have_VBP been_VBN in_IN place_NN for_IN 2005_CD and_CC to_TO the_DT date_NN of_IN approval_NN of_IN the_DT report_NN and_CC accounts_NNS ,_, involve_VB :_: the_DT identification_NN ,_, evaluation_NN and_CC management_NN of_IN key_JJ risks_NNS through_IN a_DT Risk_NNP Committee_NNP ,_, whichreports_NNS to_TO the_DT Board_NNP annually_RB :_: business_NN reviews_NNS by_IN the_DT Board_NNP :_: and_CC the_DT review_NN by_IN the_DT Audit_NNP Committee_NNP of_IN internal_JJ financial_JJ controls_NNS and_CC the_DT risk_NN management_NN process_NN ._.
These_DT systems_NNS are_VBP reviewed_VBN annually_RB by_IN the_DT Board_NNP ._.
Whilst_NNP not_RB providing_VBG absolute_JJ assurance_NN against_IN material_NN misstatements_NNS or_CC loss_NN ,_, these_DT systems_NNS are_VBP designed_VBN to_TO identify_VB and_CC manage_VB those_DT risks_NNS that_WDT could_MD adversely_RB impact_VB the_DT achievement_NN of_IN the_DT Groups_NNS objectives_NNS ._.
The_DT Group_NNP maintains_VBZ insurance_NN against_IN product_NN ,_, employers_NNS and_CC directors_NNS and_CC officers_NNS liabilities_NNS ,_, and_CC physical_JJ and_CC consequential_JJ loss_NN ,_, subject_JJ to_TO limits_NNS and_CC deductibles_NNS ._.
The_DT Group_NNP maintains_VBZ liability_NN provisions_NNS to_TO cover_VB known_JJ uninsured_JJ risks_NNS ._.
The_DT Group_NNP has_VBZ been_VBN advised_VBN that_IN three_CD insurers_NNS have_VBP declined_VBN coverage_NN for_IN macrotextured_JJ knee_NN claims_NNS ._.
